



PRESS RELEASE

For immediate distribution

SOURCE: DIAGNOS inc.



DIAGNOS Announces Inaugural Appointment to Scientific Advisory Board

Brossard, Quebec, Canada – August 25, 2009 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, announced today that it has appointed Dr. David Wong, to its Scientific Advisory Board to assist in technical and scientific validation efforts of its Computer Assisted Retinal Analysis (CARA) technology.

“We are pleased to welcome a clinician of Dr. Wong’s calibre to our Scientific Advisory Board, and look to his expertise and leadership as we continue to commercialize our CARA technology” said Mr. Andre Larente, DIAGNOS’ CEO. The appointment of Dr. Wong is part of a larger DIAGNOS effort to develop, validate, and commercialize products for the healthcare market.

DIAGNOS’ CARA technology has shown potential in clinical decision-support for ophthalmologists and for diabetic retinopathy screening. Dr. Wong has been conducting a technical test using CARA, and to date has examined well over 1,000 images with our technology.

The World Health Organisation (WHO) predicts that by 2030 there will be 366 million people suffering from diabetes, a major cause of retinopathy and vision loss. This number of sufferers is increasing at an alarming proportion year over year.

About Dr. Wong

Dr. David Wong is a Vitreoretinal Surgeon and Associate Professor of Ophthalmology at the University of Toronto. Dr. Wong specializes in diabetic retinopathy, diabetes, macular degeneration, retinal detachments, as well as trauma. He is a Fellow of The Royal College of Physicians and Surgeons of Canada, an active member of the College of Physicians and Surgeons of Ontario, and practices at Saint-Michael’s Hospital in Toronto.

About CARA

CARA (Computer Assisted Retinal Analysis) performs a proprietary enhancement of retinal images and automatically annotates potential abnormalities and indicates location, size and type of pathology to the user. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. The technology comprises a suite of pattern-matching algorithms; each algorithm has a different sensitivity and specificity for detecting a given abnormality. CARA highlights these findings for extra attention by the screener. CARA is an automated platform accessible securely over the internet, and is compatible with all recognized fundus cameras.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation (TSX: ADK), with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare, natural resources and entertainment.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations representative:

André Larente, Chief Executive Officer
Telephone: 1-877-678-8882 or (450) 678-8882, ext. 224
alarente@diagnos.com